Regramostim
- Generic Name
- Regramostim
- Drug Type
- Biotech
- CAS Number
- 127757-91-9
- Unique Ingredient Identifier
- KR89Q40F01
- Background
Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of macrophages and granulocytes and their progenitors.
- Indication
Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
Effect of rhGM-CSF on the Healing of Venous Leg Ulcers
- Conditions
- Venous Leg Ulcer
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Reponex Pharmaceuticals A/S
- Target Recruit Count
- 6
- Registration Number
- NCT04823962
- Locations
- 🇩🇰
Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital, Copenhagen, Denmark
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 30
- Registration Number
- NCT04072900
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 40
- Registration Number
- NCT03113851
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Radiation: Stereotactic body radiotherapy
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Wuhan University
- Registration Number
- NCT02623595
- Locations
- 🇨🇳
Zhongnan hospital of Wuhan university, Wuhan, Hubei, China
RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02466906
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.
- Conditions
- Pulmonary Alveolar Proteinosis
- Interventions
- Procedure: Whole Lung Lavage(WLL)
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 40
- Registration Number
- NCT01983657
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Wei LUO
- Target Recruit Count
- 160
- Registration Number
- NCT01806272
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2510
- Registration Number
- NCT01785784
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
- Conditions
- Mycoses
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT01232504
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.